CRL
Charles River LaboratoriesNYSEHealth CareDiagnostics & ResearchSnapshot 2026-05-08
As of May 8, 2026, CRL has a mixed analyst scoring with a composite score of -0.3 and a medium confidence level of 72.8. The score is influenced by various factors, including an unfavorable outlook from potential guidance cuts and labor state reversals, as well as favorable scenarios if the healthcare sector trend improves or guidance is raised. The overall risk is labeled as elevated, with notable strengths in valuation (64.4) and quality (55.0), but weaknesses in momentum (-59.5) and sector performance (7.6). This scoring is provisional.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share0.04
- Slope (norm)-0.70
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $2.90 → $2.70 (-7.1% / 30d). 0 raised, 3 cut, 9 covering analysts.
0 upgrades, 0 downgrades / 30d, 4 maintained. 71% of analysts rate Buy.
6 PT revisions / 30d. Avg target 18.5% above current price.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
10 material events in the last 24 months — top 5 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Drive efficiency and process improvementscostbehind14% progress
2/18: “CEO: 'Taking decisive actions to drive efficiency and process improvements that will deliver continued benefits.'”
Why this status
Newly stated in 2025-Q4. The financials show a decrease in operating income from $133.8M in 2025-Q3 to -$283.4M in 2025-Q4, indicating limited progress on efficiency improvements. The trajectory shows a need for substantial improvement to meet stated goals.
- 2.Selective and strategic acquisitionsgrowthmixed46% progress
2/18: “CEO: 'Committed to driving our strategy forward, including through selective and strategic acquisitions.'”
Why this status
Newly stated in 2025-Q4. The financials do not show immediate impact from acquisitions, with revenue decreasing from $1.00B in 2025-Q3 to $994.2M in 2025-Q4. The trajectory for acquisitions is not yet clear, requiring further monitoring.
- 3.Strengthen and refine organizationtalentmixed65% progress
2/18: “CEO: 'Strengthening and refining our organization to enhance our speed and responsiveness.'”
Why this status
Newly stated in 2025-Q4. The financials indicate a net loss of $276.6M in 2025-Q4, suggesting that organizational enhancements have not yet translated into financial improvements. The trajectory remains uncertain, with further efforts needed to achieve stated goals.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 51%; 252d 43%.
Drawdown — Max 1y −33%. Bad day move −4%.
Beta to sector ETF (XLV) — 1.42 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 28/100, drawdown 34/100, beta 58/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Drive efficiency and process improvements
CostFocus on efficiency and process improvements to deliver continued benefits.
BehindNewly stated in 2025-Q4. The financials show a decrease in operating income from $133.8M in 2025-Q3 to -$283.4M in 2025-Q4, indicating limited progress on efficiency improvements. The trajectory shows a need for substantial improvement to meet stated goals.
14%CEO/CFO:“CEO: 'Taking decisive actions to drive efficiency and process improvements that will deliver continued benefits.'”Press releaseSource dated 2026-02-18Stated 1 of last 8 quartersFirst seen 2026-02-18Show history (1)
- 2025-Q4Press release
“CEO: 'Taking decisive actions to drive efficiency and process improvements...'”
- #2
Selective and strategic acquisitions
GrowthPursue selective and strategic acquisitions that align with core competencies.
MixedNewly stated in 2025-Q4. The financials do not show immediate impact from acquisitions, with revenue decreasing from $1.00B in 2025-Q3 to $994.2M in 2025-Q4. The trajectory for acquisitions is not yet clear, requiring further monitoring.
46%CEO/CFO:“CEO: 'Committed to driving our strategy forward, including through selective and strategic acquisitions.'”Press releaseSource dated 2026-02-18Stated 1 of last 8 quartersFirst seen 2026-02-18Show history (1)
- 2025-Q4Press release
“CEO: '...through selective and strategic acquisitions that align with our core competencies.'”
- #3
Strengthen and refine organization
TalentEnhance speed and responsiveness by strengthening and refining the organization.
MixedNewly stated in 2025-Q4. The financials indicate a net loss of $276.6M in 2025-Q4, suggesting that organizational enhancements have not yet translated into financial improvements. The trajectory remains uncertain, with further efforts needed to achieve stated goals.
65%CEO/CFO:“CEO: 'Strengthening and refining our organization to enhance our speed and responsiveness.'”Press releaseSource dated 2026-02-18Stated 1 of last 8 quartersFirst seen 2026-02-18Show history (1)
- 2025-Q4Press release
“CEO: '...strengthening and refining our organization to enhance our speed and responsiveness.'”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks more expensive than peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
48 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
CRL Charles River Laboratories | -0.3 | fair | elevated |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently REAFFIRMED as of 2026-05-07)+4.0 pts
- If next-quarter guidance is cut (currently REAFFIRMED as of 2026-05-07)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-071d agoItem 2.02
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On May 7, 2026, Charles River Laboratories International, Inc. issued a press release providing financial re…
earnings preannouncement—score 64 - 2026-02-182mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 18, 2026, the Company announced the appointment of Glenn Coleman as its Corporate Executive Vice President and Chief Financial Officer. Mr. Coleman will join the company with a tentative start date of April 6, 2026. Mr. Coleman, 58, will join Charles River with over 30 years of strong financial and operational management experience, inc…
executive changeneutralscore 13 - 2026-02-182mo agoItem 2.02
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On February 18, 2026, Charles River Laboratories International, Inc. issued a press release providing financ…
earnings preannouncementneutralscore 11 - 2026-02-252mo agoItem 7.01
Regulation FD Disclosure The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Planned Divestiture of CDMO and Cell Solutions Businesses On February 25, 2026, Charles River Laboratories International, Inc. (t…
mna activityneutralscore 10 - 2026-01-093mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Chief Executive Officer Transition On January 8, 2026, the Board of Directors (the “Board”) of Charles River Laboratories International, Inc. (the “Company”) announced a leadership transition plan. Mr. James C. Foster, our current Chairman of the Board, President and Chief Executive Officer, intends to step down as Chief Executive Officer and Chairm…
executive changeneutralscore 5
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.